NeoRecormon

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

epoetin beta

Available from:

Roche Registration GmbH

ATC code:

B03XA01

INN (International Name):

epoetin beta

Therapeutic group:

Antianemic preparations

Therapeutic area:

Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous

Therapeutic indications:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

Product summary:

Revision: 33

Authorization status:

Authorised

Authorization date:

1997-07-16

Patient Information leaflet

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEORECORMON 500 IU
NEORECORMON 2000 IU
NEORECORMON 3000 IU
NEORECORMON 4000 IU
NEORECORMON 5000 IU
NEORECORMON 6000 IU
NEORECORMON 10,000 IU
NEORECORMON 20,000 IU
NEORECORMON 30,000 IU
SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs or illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What NeoRecormon is and what it is used for
2.
What you need to know before you use NeoRecormon
3.
How to use NeoRecormon
4.
Possible side effects
5.
How to store NeoRecormon
6.
Content of the pack and other information
1.
WHAT NEORECORMON IS AND WHAT IT IS USED FOR
NeoRecormon is a clear, colourless solution for injection under the
skin
_(subcutaneously)_
or into a
vein
_(intravenously). _
It contains a hormone called
_epoetin beta_
, which stimulates the production of red
blood cells. Epoetin beta is produced by a specialised genetic
technology and works in exactly the
same way as the natural hormone erythropoietin.
You must talk to your doctor if you do not feel better or if you feel
worse.
NeoRecormon is indicated for:
•
TREATING SYMPTOMATIC ANAEMIA CAUSED BY CHRONIC KIDNEY DISEASE
(renal anaemia) in patients
on dialysis, or not yet on dialysis.
•
PREVENTING ANAEMIA IN PREMATURE INFANTS
(weighing 750 to 1500 g and born at less than
34 weeks).
•
TREATING ANAEMIA WITH RELATED SYMPTOMS IN ADULT CANCER PATIENTS
RECEIVING CHEMOTHERAPY
•
TREATING PEOPLE DONATING THEIR OWN BLOOD BEFORE SURGERY.
The injections of epoetin beta will
increas
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
NeoRecormon 500 IU solution for injection in pre-filled syringe
NeoRecormon 2000 IU solution for injection in pre-filled syringe
NeoRecormon 3000 IU solution for injection in pre-filled syringe
NeoRecormon 4000 IU solution for injection in pre-filled syringe
NeoRecormon 5000 IU solution for injection in pre-filled syringe
NeoRecormon 6000 IU solution for injection in pre-filled syringe
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 20,000 IU solution for injection in pre-filled syringe
NeoRecormon 30,000 IU solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NeoRecormon 500 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains 500
international units (IU)
corresponding to 4.15 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 1667 IU epoetin beta.
NeoRecormon 2000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
2000 international units (IU)
corresponding to 16.6 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 6667 IU epoetin beta.
NeoRecormon 3000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
3000 international units (IU)
corresponding to 24.9 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 10,000 IU epoetin beta.
NeoRecormon 4000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
4000 international units (IU)
corresponding to 33.2 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 13,333 IU epoetin beta.
NeoRecormon 5000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-03-2023
Public Assessment Report Public Assessment Report Bulgarian 03-12-2015
Patient Information leaflet Patient Information leaflet Spanish 15-03-2023
Public Assessment Report Public Assessment Report Spanish 03-12-2015
Patient Information leaflet Patient Information leaflet Czech 15-03-2023
Public Assessment Report Public Assessment Report Czech 03-12-2015
Patient Information leaflet Patient Information leaflet Danish 15-03-2023
Public Assessment Report Public Assessment Report Danish 03-12-2015
Patient Information leaflet Patient Information leaflet German 15-03-2023
Public Assessment Report Public Assessment Report German 03-12-2015
Patient Information leaflet Patient Information leaflet Estonian 15-03-2023
Public Assessment Report Public Assessment Report Estonian 03-12-2015
Patient Information leaflet Patient Information leaflet Greek 15-03-2023
Public Assessment Report Public Assessment Report Greek 03-12-2015
Patient Information leaflet Patient Information leaflet French 15-03-2023
Public Assessment Report Public Assessment Report French 03-12-2015
Patient Information leaflet Patient Information leaflet Italian 15-03-2023
Public Assessment Report Public Assessment Report Italian 03-12-2015
Patient Information leaflet Patient Information leaflet Latvian 15-03-2023
Public Assessment Report Public Assessment Report Latvian 03-12-2015
Patient Information leaflet Patient Information leaflet Lithuanian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-03-2023
Public Assessment Report Public Assessment Report Lithuanian 03-12-2015
Patient Information leaflet Patient Information leaflet Hungarian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 15-03-2023
Public Assessment Report Public Assessment Report Hungarian 03-12-2015
Patient Information leaflet Patient Information leaflet Maltese 15-03-2023
Public Assessment Report Public Assessment Report Maltese 03-12-2015
Patient Information leaflet Patient Information leaflet Dutch 15-03-2023
Public Assessment Report Public Assessment Report Dutch 03-12-2015
Patient Information leaflet Patient Information leaflet Polish 15-03-2023
Public Assessment Report Public Assessment Report Polish 03-12-2015
Patient Information leaflet Patient Information leaflet Portuguese 15-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 15-03-2023
Public Assessment Report Public Assessment Report Portuguese 03-12-2015
Patient Information leaflet Patient Information leaflet Romanian 15-03-2023
Public Assessment Report Public Assessment Report Romanian 03-12-2015
Patient Information leaflet Patient Information leaflet Slovak 15-03-2023
Public Assessment Report Public Assessment Report Slovak 03-12-2015
Patient Information leaflet Patient Information leaflet Slovenian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 15-03-2023
Public Assessment Report Public Assessment Report Slovenian 03-12-2015
Patient Information leaflet Patient Information leaflet Finnish 15-03-2023
Public Assessment Report Public Assessment Report Finnish 03-12-2015
Patient Information leaflet Patient Information leaflet Swedish 15-03-2023
Public Assessment Report Public Assessment Report Swedish 03-12-2015
Patient Information leaflet Patient Information leaflet Norwegian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 15-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 15-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 15-03-2023
Patient Information leaflet Patient Information leaflet Croatian 15-03-2023
Public Assessment Report Public Assessment Report Croatian 03-12-2015

Search alerts related to this product

View documents history